読み込み中
HKSEHealthcareMedical - Pharmaceuticals
最新データ
HK$5.69
+HK$0.025 · +0.44%
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
最新データ
HK$5.69
+HK$0.025 · +0.44%
日中の時刻はHKTです。市場データは遅延する場合があります。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日中レンジ
現在 HK$5.69
52週レンジ
現在 HK$5.69
日中の時刻はHKTです。市場データは遅延する場合があります。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日中レンジ
現在 HK$5.69
52週レンジ
現在 HK$5.69
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 87.55億 CNY | 84.66億 CNY | 81.01億 CNY | 75.03億 CNY | 65.6億 CNY |
| 売上原価 | 71.1億 CNY | 64.25億 CNY | 57.79億 CNY | 54.66億 CNY | 47.86億 CNY |
| 粗利益 | 16.45億 CNY | 20.42億 CNY | 23.21億 CNY | 20.37億 CNY | 17.74億 CNY |
| 研究開発 | 4.4億 CNY | 4.13億 CNY | 4.19億 CNY | 3.46億 CNY | 3.41億 CNY |
| 販売・一般管理 | 3.41億 CNY | 6.08億 CNY | 12.98億 CNY | 8.15億 CNY | 6.89億 CNY |
| 営業費用 | 12.28億 CNY | 15.07億 CNY | 17.87億 CNY | 14.94億 CNY | 12.75億 CNY |
| 受取利息 | 748.65万 CNY | 1112.55万 CNY | 937.68万 CNY | 1046.2万 CNY | 877.63万 CNY |
| 支払利息 | 4333.2万 CNY | 3973.93万 CNY | 4114.86万 CNY | 4970.69万 CNY | 5310.34万 CNY |
| 減価償却費と償却費 | 5.88億 CNY | 5.41億 CNY | 5.17億 CNY | 4.85億 CNY | 4.34億 CNY |
| 営業利益 | 3.64億 CNY | 5.34億 CNY | 5.35億 CNY | 4.77億 CNY | 4.26億 CNY |
| 純利益 | 2.9億 CNY | 4.7億 CNY | 4.97億 CNY | 4.11億 CNY | 3.49億 CNY |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
分割調整後の1株当たりの年間現金分配金。
HK$0.2731
2025年（通年）+51.7% 以来 2021
2026年（一部）：HK$0.1725
HK$0.1801
2,021
HK$0.1758
2,022
HK$0.2189
2,023
HK$0.3014
2,024
HK$0.2731
2,025
HK$0.1725
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年7月10日 | HK$0.1725Annual | 2026年7月13日 | 2026年7月31日 |
配当 | 2025年6月27日 | HK$0.2731Semi-Annual | 2025年6月30日 | 2025年7月18日 |
配当 | 2024年9月4日 | HK$0.0273Semi-Annual | 2024年9月5日 | 2024年9月27日 |
配当 | 2024年7月10日 | HK$0.2741Semi-Annual | 2024年7月11日 | 2024年7月30日 |
配当 | 2023年7月7日 | HK$0.2189Annual | 2023年7月10日 | 2023年7月26日 |
配当 | 2022年7月15日 | HK$0.1758Annual | 2022年7月18日 | 2022年8月5日 |
配当落ち 2026年7月10日
HK$0.1725
Annual
2026年7月13日基準 · 支払日 2026年7月31日
配当落ち 2025年6月27日
HK$0.2731
Semi-Annual
2025年6月30日基準 · 支払日 2025年7月18日
配当落ち 2024年9月4日
HK$0.0273
Semi-Annual
2024年9月5日基準 · 支払日 2024年9月27日
配当落ち 2024年7月10日
HK$0.2741
Semi-Annual
2024年7月11日基準 · 支払日 2024年7月30日
配当落ち 2023年7月7日
HK$0.2189
Annual
2023年7月10日基準 · 支払日 2023年7月26日
配当落ち 2022年7月15日
HK$0.1758
Annual
2022年7月18日基準 · 支払日 2022年8月5日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Emerging Markets Small Cap ETFEWX23.37万0.03%6.65億 USD0.65%$71.64+1.00%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM15.74万0.00%96.67億 USD0.39%$40.01+1.07%
Dimensional - Emerging Core Equity Market ETFDFAE13.57万0.00%101.12億 USD0.29%$39.40+0.97%
Dimensional World ex U.S. Core Equity 2 ETFDFAX10.05万0.00%123.36億 USD0.28%$37.08+0.76%
Dimensional - Emerging Markets Value ETFDFEV5.05万0.00%21.87億 USD0.46%$42.58+1.00%State Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
